{
    "2018-08-14": [
        [
            {
                "time": "2018-11-05",
                "original_text": "Novo Nordisk's Pricing Pressures Aren't Going Away",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "pricing pressures",
                        "away"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-11-05",
                "original_text": "European ADRs Move Higher in Tuesday Trading",
                "features": {
                    "keywords": [
                        "European",
                        "ADRs",
                        "move higher",
                        "trading"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-05",
                "original_text": "A Look at Novo Nordisk’s Human Insulin and Obesity Business",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "human insulin",
                        "obesity business"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-11-05",
                "original_text": "How Novo Nordisk’s Premix Insulin Is Positioned after H1 2018",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "premix insulin",
                        "positioned",
                        "H1 2018"
                    ],
                    "sentiment_score": 0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-11-05",
                "original_text": "What Drove GlaxoSmithKline’s Consumer Healthcare Segment in Q2",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "consumer healthcare",
                        "segment",
                        "Q2"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-11-05",
                "original_text": "Novo Nordisk’s Fast-Acting Insulins: A Performance Overview",
                "features": {
                    "keywords": [
                        "Novo Nordisk",
                        "fast-acting insulins",
                        "performance overview"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}